News
MGTX
13.77
+8.68%
1.10
MeiraGTx Holdings Is Maintained at Outperform by RBC Capital
Dow Jones · 5h ago
MeiraGTx Holdings Price Target Raised to $27.00/Share From $26.00 by RBC Capital
Dow Jones · 5h ago
RBC Capital Maintains Outperform on MeiraGTx Holdings, Raises Price Target to $27
Benzinga · 5h ago
RBC Capital Sticks to Their Buy Rating for Meiragtx Holdings (MGTX)
TipRanks · 8h ago
Bank of America Securities Remains a Buy on Meiragtx Holdings (MGTX)
TipRanks · 9h ago
Mitchell Kapoor Reiterates Buy on MeiraGTx, Maintains $20 12-Month Price Target on Clinical Progress and Strengthened Balance Sheet
TipRanks · 1d ago
MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
NASDAQ · 1d ago
MeiraGTx Hldgs Q2 EPS $1.71 Beats $(0.46) Estimate, Sales $321.434M Beat $12.476M Estimate
Benzinga · 1d ago
MeiraGTx Hldgs Q2 Sales $321.434M Beat $12.476M Estimate
Benzinga · 1d ago
*MeiraGTx Holdings 2Q Rev $321.4M >MGTX
Dow Jones · 1d ago
*MeiraGTx Holdings 2Q EPS $1.71 >MGTX
Dow Jones · 1d ago
Press Release: MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
Dow Jones · 1d ago
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
NASDAQ · 2d ago
Weekly Report: what happened at MGTX last week (0803-0807)?
Weekly Report · 4d ago
Weekly Report: what happened at MGTX last week (0727-0731)?
Weekly Report · 08/03 09:13
Some Potential Merit Within MeiraGTx Holdings
Seeking Alpha · 07/30 16:57
Weekly Report: what happened at MGTX last week (0720-0724)?
Weekly Report · 07/27 09:14
Weekly Report: what happened at MGTX last week (0713-0717)?
Weekly Report · 07/20 09:13
Weekly Report: what happened at MGTX last week (0706-0710)?
Weekly Report · 07/13 09:13
What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near
The Motley Fool · 07/12 19:39
More
Webull provides a variety of real-time MGTX stock news. You can receive the latest news about Meiragtx Holdings Plc through multiple platforms. This information may help you make smarter investment decisions.
About MGTX
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.